← Oncology Approval Tracker

FDA DECISION ·

Zimrixby

rituximab-cdxx · Dr. Reddy’s Laboratories

Biosimilar approvalBiosimilarB-cell lymphoma and CLL
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Rituxan biosimilar with labeled adult oncology uses in non-Hodgkin lymphoma and CLL, including specified combination, monotherapy and maintenance settings.

LAMPGEN ANALYSIS

Why it matters

A rituximab biosimilar can expand purchasing options for established CD20-directed regimens. Its approval rests on biosimilarity to the reference product.

What research teams should watch

Verify the specific oncology use in the product label and capture product identity in infusion records and safety reporting.

PRIMARY RECORDS

Sources